

REFERENCES

- Hany M, Rehman B, Azhar Y, et al. Schizophrenia. [Updated 2023 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539864/>
- Esfahlani, F. Z., Sayama, H., Visser, K. F., & Strauss, G. P. (2017). Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis. *Innovations in clinical neuroscience*, 14(11-12), 59–67.
- A Systematic Review of Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Dec. (CADTH Optimal Use Report, No. 1.1B.) APPENDIX 3, VALIDITY OF PSYCHIATRIC SYMPTOM SCALES AND CLINICAL IMPLICATIONS. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK169692/>
- Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., ... & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. *Schizophrenia bulletin*, 44(6), 1195-1203.
- Stepnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current concepts and treatments of schizophrenia. *Molecules*, 23(8), 2087.
- Stroup, T. S., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. *World psychiatry : official journal of the World Psychiatric Association (WPA)*, 17(3), 341–356. <https://doi.org/10.1002/wps.20567>
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: overview and treatment options. *P & T : a peer-reviewed journal for formulary management*, 39(9), 638–645.
- Ainni, A. N., & Rahmawati, F. (2022, December). The Adverse Drug Reactions on Antipsychotic Use in Residual Schizophrenia Outpatients at Hospital in

- Purworejo, Central Java, Indonesia. In 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022) (pp. 164-174). Atlantis Press.
- Singal, A. G., Higgins, P. D. R., & Waljee, A. K. (2014). A Primer on Effectiveness and Efficacy Trials. *Clinical and Translational Gastroenterology*, 5(1), e45. <https://doi.org/10.1038/ctg.2013.13>
- VA Center for Medication Safety, VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. (2006). Adverse Drug Events, Adverse Drug Reactions.
- Karge, R. A., Curtain, C. M., & Salahudeen, M. S. (2023). Community Pharmacists' Role in Reducing the Incidence of Cardiometabolic Adverse Drug Events in Schizophrenia: Insights from Mental Health Professionals. *Medicina*, 59(12), 2052.
- Pourhoseingholi, M. A., Vahedi, M., & Rahimzadeh, M. (2013). Sample size calculation in medical studies. *Gastroenterology and Hepatology from bed to bench*, 6(1), 14.
- Bates, D. W. (1995). Incidence of Adverse Drug Events and Potential Adverse Drug Events. *JAMA*, 274(1), 29. doi:10.1001/jama.1995.03530010043033
- Rojas-Valladares, E., Aguilar-Salas, I., Sánchez-Herrera, K., Heyerdahl-Viau, I., Benitez-Morales, J., & Martínez-Núñez, J. M. (2024). Analysis of Adverse Drug Reactions caused by antipsychotic drugs in a Mexican health institute. *Revista de la Facultad de Medicina Humana*, 24(1), 5.
- Hartwig, S. C., Siegel, J., & Schneider, P. J. (1992). Preventability and severity assessment in reporting adverse drug reactions. *American journal of hospital pharmacy*, 49(9), 2229-2232.
- Blazer, D. G., & Hernandez, L. M. (Eds.). (2006). Genes, behavior, and the social environment: Moving beyond the nature/nurture debate.
- Lloyd, J., Lloyd, H., Fitzpatrick, R., & Peters, M. (2017). Treatment outcomes in schizophrenia: Qualitative study of the views of family carers. *BMC Psychiatry*, 17, 266. <https://doi.org/10.1186/s12888-017-1418-8>

- Tulchinsky, T. H., & Varavikova, E. A. (2014). Measuring, monitoring, and evaluating the health of a population. *The New Public Health*, 91.
- Pollack, M. M. (2016). Severity of illness confusion. *Pediatric critical care medicine*, 17(6), 583.
- McGrath, J. J., Lim, C. C. W., Plana-Ripoll, O., Holtz, Y., Agerbo, E., Momen, N. C., Mortensen, P. B., Pedersen, C. B., Abdulmalik, J., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Bromet, E. J., Bruffaerts, R., Bunting, B., Almeida, J. M. C. de, Girolamo, G. de, Vries, Y. A. D., Florescu, S., ... Jonge, P. de. (2020). Comorbidity within mental disorders: A comprehensive analysis based on 145 990 survey respondents from 27 countries. *Epidemiology and Psychiatric Sciences*, 29, e153. <https://doi.org/10.1017/S2045796020000633>
- Falola, O., Osamor, V. C., Adebisi, M., & Adebisi, E. (2017). Analyzing a single nucleotide polymorphism in schizophrenia: a meta-analysis approach. *Neuropsychiatric disease and treatment*, 2243-2250.
- Harrison, P. J. (2015). Recent genetic findings in schizophrenia and their therapeutic relevance. *Journal of psychopharmacology*, 29(2), 85-96.
- Montoya, A., Valladares, A., Lizán, L., San, L., Escobar, R., & Paz, S. (2011). Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. *Health and quality of life outcomes*, 9, 1-11.
- D'Souza, R. S., Mercogliano, C., Ojukwu, E., D'Souza, S., Singles, A., Modi, J., ... & Donato, A. (2018). Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis. *Emergency Medicine Journal*, 35(5), 325-331.
- Greil, W., Häberle, A., Schuhmann, T., Grohmann, R., & Baumann, P. (2013). Age and adverse drug reactions from psychopharmacological treatment.
- Galbally, M., Wynter, K., Siskind, D., Correll, C. U., Northwood, K., & Every-Palmer, S. (2024). Sex differences between female and male

individuals in antipsychotic efficacy and adverse effects in the treatment of schizophrenia. *CNS drugs*, 38(7), 559-570.

Mayer, J., Vasic, N., Wolf, V., Steiner, I., Klein, V., Fritz, M., ... & Dudeck, M. (2022). Gender differences in the psychopharmacological treatment of forensic in-patients with schizophrenia. *Frontiers in Psychiatry*, 13, 907123.

Khasawneh, F. T., & Shankar, G. S. (2014). Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. *Cardiology research and practice*, 2014(1), 273060.

Zhang, J. P., & Malhotra, A. K. (2011). Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. *Expert opinion on drug metabolism & toxicology*, 7(1), 9-37.

Yoshida, K., & Müller, D. J. (2019). Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. *Molecular Neuropsychiatry*, 5(Suppl. 1), 1-26.

Fortinguerra, S., Sorrenti, V., Giusti, P., Zusso, M., & Buriani, A. (2019). Pharmacogenomic characterization in bipolar spectrum disorders. *Pharmaceutics*, 12(1), 13.

Wang, X., Mei, D., Lu, Z., Zhang, Y., Sun, Y., Lu, T., ... & Yue, W. (2023). Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. *Schizophrenia*, 9(1), 44.

Basile, V. S., Masellis, M., Potkin, S. G., & Kennedy, J. L. (2002). Pharmacogenomics in schizophrenia: the quest for individualized therapy. *Human molecular genetics*, 11(20), 2517-2530.

Arranz, M. J., & De Leon, J. (2007). Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. *Molecular psychiatry*, 12(8), 707-747.

Rahman, S., & Marwaha, R. (2020). Haloperidol.

Weinbrenner, S., Assion, H. J., Stargardt, T., Busse, R., Juckel, G., & Gericke, C. A. (2009). Drug prescription patterns in schizophrenia outpatients: analysis

- of data from a German health insurance fund. *Pharmacopsychiatry*, 42(02), 66-71.
- Wang, J., Jiang, F., Zhang, Y., Cotes, R. O., Yang, Y., Liu, Z., ... & Liu, H. (2021). Patterns of antipsychotic prescriptions in patients with schizophrenia in China: a national survey. *Asian journal of psychiatry*, 62, 102742.
- Julaeha, J., Athiyah, U., & Hermansyah, A. (2019). The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting. *Journal of Basic and Clinical Physiology and Pharmacology*, 30(6), 20190289.
- Ostinelli, E. G., Brooke-Powney, M. J., Li, X., & Adams, C. E. (2017). Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database of Systematic Reviews*, (7).
- Ballon, J., & Stroup, T. S. (2013). Polypharmacy for schizophrenia. *Current opinion in psychiatry*, 26(2), 208-213.
- National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 23663956, Divalproex Sodium. Retrieved March 20, 2025 from <https://pubchem.ncbi.nlm.nih.gov/compound/Divalproex-Sodium>.
- Sherer, J., Salazar, T., Schesing, K. B., McPartland, S., & Kornitzer, J. (2017). Diphenhydramine for acute extrapyramidal symptoms after propofol administration. *Pediatrics*, 139(2).
- Sheikh, W. A. (2019). Prophylactic use of trihexyphenidyl (artane) in schizophrenia and psychosis: a critical review of literature to guide for evidence based practice in Zambia. *Medical Journal of Zambia*, 46(2), 133-139.
- McLendon, K., & Preuss, C. V. (2023). Atropine. In *StatPearls* [Internet]. StatPearls Publishing.
- Van der Poorten, T., & De Hert, M. (2019). The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: A systematic review. *Clinical Case Reports*, 7(11), 2108-2113.

- Tesli, M., Degerud, E., Plana-Ripoll, O., Gustavson, K., Torvik, F. A., Ystrom, E., Ask, H., Tesli, N., Høye, A., Stoltenberg, C., Reichborn-Kjennerud, T., Nesvåg, R., & Naess, Ø. (2022). Educational attainment and mortality in schizophrenia. *Acta psychiatrica Scandinavica*, 145(5), 481–493. <https://doi.org/10.1111/acps.13407>
- Amin, M. M., Effendy, E., & Loebis, B. (2020). Cognitive Profile of Patients with Schizophrenia in North Sumatera Indonesia. *Open Access Macedonian Journal of Medical Sciences*, 8(B), 683-686.
- Elistiana, D. I., Aristiani, W., & Yuniasih, D. (2024). Characteristics of Schizophrenia Patients at Kasihan II Bantul Public Health Center in 2022. *Ahmad Dahlan Medical Journal*, 5(1), 54-62.
- Setiawati, N. M. (2020). Differences in Sociodemographic Characteristics of Schizophrenia Patients between Rural and Urban Areas in Badung Regency. *WMJ (Warmadewa Medical Journal)*, 5(2), 76-84.
- Holm, M., Taipale, H., Tanskanen, A., Tiihonen, J., & Mitterdorfer-Rutz, E. (2021). Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. *Acta Psychiatrica Scandinavica*, 143(1), 61-71.
- Velelekou, A., Papathanasiou, I. V., Alikari, V., Papagiannis, D., Tsaras, K., & Fradelos, E. C. (2022). Factors influencing the duration of hospitalization of patients with schizophrenia. *Medicine and Pharmacy Reports*, 95(3), 290.
- Cohen, D., Stolk, R. P., Grobbee, D. E., & Gispen-de Wied, C. C. (2006). Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. *Diabetes care*, 29(4), 786-791.
- Hynes, C., McWilliams, S., Clarke, M., Fitzgerald, I., Feeney, L., Taylor, M., ... & Keating, D. (2020). Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort. *Therapeutic advances in psychopharmacology*, 10, 2045125320957119.
- Seppälä, A., Pylvänäinen, J., Lehtiniemi, H., Hirvonen, N., Corripio, I., Koponen, H., ... & Jääskeläinen, E. (2021). Predictors of response to

pharmacological treatments in treatment-resistant schizophrenia—a systematic review and meta-analysis. *Schizophrenia Research*, 236, 123-134.

Severance, E. G., Prandovszky, E., Castiglione, J., & Yolken, R. H. (2015). Gastroenterology issues in schizophrenia: why the gut matters. *Current psychiatry reports*, 17, 1-10.

Diniz, E., Fonseca, L., Rocha, D., Trevizol, A., Cerqueira, R., Ortiz, B., ... & Gadelha, A. (2023). Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. *Brazilian Journal of Psychiatry*, 45, 448-458.

Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P., Chele, G., & Szalontay, A. S. (2023). Benzodiazepines and mood stabilizers in schizophrenia patients treated with oral versus long-acting injectable antipsychotics—an observational study. *Brain sciences*, 13(2), 173.

Agrawal, M., Borkar, S., & Kale, S. (2019). Phenytoin toxicity manifesting as acute psychosis: An uncommon side effect of a common drug. *Asian Journal of Neurosurgery*, 14(02), 532-534.

Jilani, T. N., Sabir, S., Patel, P., & Sharma, S. (2024). Trihexyphenidyl. In *StatPearls [Internet]*. StatPearls Publishing.

Ali, S. N., & Bazzano, L. A. (2018). Hyponatremia in association with second-generation antipsychotics: a systematic review of case reports. *Ochsner Journal*, 18(3), 230-235.

Annamalai, A., & Tek, C. (2015). An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. *International journal of endocrinology*, 2015(1), 969182.

Holt, R. I. (2019). Association between antipsychotic medication use and diabetes. *Current diabetes reports*, 19(10), 96.

Helfer, B., Samara, M. T., Huhn, M., Klupp, E., Leucht, C., Zhu, Y., ... & Leucht, S. (2016). Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. *American Journal of Psychiatry*, 173(9), 876-886.

- Kennedy, E., Song, F., Hunter, R., Clarke, A., & Gilbody, S. (2003). Risperidone versus typical antipsychotic medication for schizophrenia. The Cochrane database of systematic reviews, 2003(2), CD000440.
<https://doi.org/10.1002/14651858.CD000440>
- Haddad, P. M., & Correll, C. U. (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. *Therapeutic advances in psychopharmacology*, 8(11), 303-318.
- Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., ... & Davis, J. M. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *American Journal of Psychiatry*, 174(10), 927-942.
- Kakar, G., Mehendale, A. M., Sadh, K., Bakshi, S. S., Bodke, H., & Krishnani, H. (2023). A Phenomenal Depiction of Paranoid Schizophrenia With Auditory Hallucinations: A Case Report. *Cureus*, 15(9).
- Jain, A., & Mitra, P. (2020). Catatonic schizophrenia.
- Gammon, D., Cheng, C., Volkovinskaia, A., Baker, G. B., & Dursun, S. M. (2021). Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders?. *Biomolecules*, 11(7), 1030.
- Ayani, N., Morimoto, T., Sakuma, M., Kikuchi, T., Watanabe, K., & Narumoto, J. (2021). Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study. *Journal of clinical psychopharmacology*, 41(4), 397–402.
<https://doi.org/10.1097/JCP.0000000000001416>
- Šimunović Filipčić, I., & Filipčić, I. (2018). Schizophrenia and physical comorbidity. *Psychiatria Danubina*, 30(suppl. 4), 152-157.
- van Dee, V., Kia, S. M., Winter-van Rossum, I., Kahn, R. S., Cahn, W., & Schnack, H. G. (2023). Revealing the impact of psychiatric comorbidities on treatment outcome in early psychosis using counterfactual model explanation. *Frontiers in psychiatry*, 14, 1237490.
<https://doi.org/10.3389/fpsy.2023.1237490>

- Desai, R., & Nayak, R. (2019). Effects of Medication Nonadherence and Comorbidity on Health Resource Utilization in Schizophrenia. *Journal of managed care & specialty pharmacy*, 25(1), 37–46.
<https://doi.org/10.18553/jmcp.2019.25.1.037>
- Khandker, R., Qureshi, Z. P., Shepherd, J., Samant, S., Chekani, F., & Bailey, H. M. (2020). A Real-World Assessment of Outcomes in Schizophrenia Patients According to Treatment Response. *The Primary Care Companion for CNS Disorders*, 22(6), 25684.
- Pålsson, P., Guldberg, J., Gustafsson, J. M., & Aiff, H. (2022). Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil. *The American journal of case reports*, 23, e938387.
<https://doi.org/10.12659/AJCR.938387>
- Thippaiah, S. M., Fargason, R. E., & Birur, B. (2021). Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!. *Psychopharmacology bulletin*, 51(3), 72–78.
- Gugger J. J. (2011). Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. *CNS drugs*, 25(8), 659–671.
<https://doi.org/10.2165/11591710-0000000000-00000>
- Kosmalski, M., Różycka-Kosmalska, M., Basiak, M., Okopień, B., & Pietras, T. (2022). Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs. *Endokrynologia Polska*, 73(5), 872–884.
<https://doi.org/10.5603/EP.a2022.0071>
- Bukić, J., Herceg, D., Modun, D., Krce, I., Leskur, D., Durdov, T., Herceg, M., Šešelja Perišin, A., & Rušić, D. (2024). Evaluating Adverse Drug Reactions, Their Reporting Rates and Their Impact on Attitudes Toward Pharmacotherapy Among Female Patients with Schizophrenia: Insights and Implications from a Cross-Sectional Study. *Healthcare*, 12(24), 2595.
<https://doi.org/10.3390/healthcare12242595>
- Montes, J. M., Agüera-Ortiz, L., Mané, A., Martínez-Raga, J., & Gutiérrez-Rojas, L. (2024). Clinical decision-making before discharge in hospitalized

- persons with schizophrenia: a Spanish Delphi expert consensus. *Frontiers in psychiatry*, 15, 1412637. <https://doi.org/10.3389/fpsyt.2024.1412637>
- Siragusa S, Bistas KG, Saadabadi A. Fluphenazine. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459194/>
- Lähteenvu, M., & Tiihonen, J. (2021). Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. *Drugs*, 81(11), 1273–1284. <https://doi.org/10.1007/s40265-021-01556-4>
- Mustikawati, M. S. A., Budiman, B. H. Y. L., & Ikawati, Z. Efficacy and safety of clozapine combination with different antipsychotics in schizophrenia: a systematic review. *Indonesian Journal of Pharmacology and Therapy*, 5(1).
- Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, 162(1), 130-136.
- Pringsheim, T., Doja, A., Belanger, S., Patten, S., & Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group (2011). Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. *Paediatrics & child health*, 16(9), 590–598.